These figures pool every individual call made by Guggenheim's analysts into a single sample — so a prolific analyst carries more weight than a low-volume one, exactly in proportion to the evidence available. All metrics are computed independently by 13Foresight from historical prices.
| Analyst | Our Rank | Stars | Success | Avg Return | vs S&P | Calls |
|---|---|---|---|---|---|---|
| Pro analyst | — | — | — | — | — | — |
| Pro analyst | — | — | — | — | — | — |
| Pro analyst | — | — | — | — | — | — |
| Pro analyst | — | — | — | — | — | — |
| Pro analyst | — | — | — | — | — | — |
| Pro analyst | — | — | — | — | — | — |
| Jacob Smith CFA | #1017 | ★★★ | 50% | -2.3% | -6.2% | 4 |
| John Heinbockel | #1308 | ★★★ | 49% | -3.9% | -4.8% | 35 |
| Steven Forbes | #1484 | ★★★ | 48% | +3.4% | -4.2% | 25 |
| Ronald Jewsikow | #1881 | ★★ | 36% | -3.3% | -17.6% | 11 |
| Seamus Fernandez | #1946 | ★★ | 48% | +3.2% | -75.9% | 40 |
| Michael Schmidt | #1979 | ★★ | 55% | +12.1% | -94.8% | 65 |
| Yatin Suneja | #2041 | ★★ | 51% | -0.9% | -8.1% | 49 |
| Gregory Francfort | #2044 | ★★ | 48% | +4.7% | -83.4% | 21 |
| Joseph Osha | #2101 | ★★ | 54% | +2.6% | -9.4% | 41 |
| Subbu Nambi | #2111 | ★★ | 40% | +1.1% | -50.1% | 30 |
| Paul Jeng | #2121 | ★★ | 14% | -17.5% | -25.8% | 7 |
| Simeon Siegel | #2145 | ★★ | 50% | -2.2% | -87.4% | 42 |
| Michael Morris | #2187 | ★★ | 31% | -5.6% | -10.3% | 29 |
| Jonathan Lee CFA | #2349 | ★ | 15% | -14.4% | -24.3% | 13 |
| Bradley Canino | #2359 | ★ | 55% | -8.4% | -59.7% | 29 |
| Debjit Chattopadhyay | #2548 | ★ | 36% | -2.1% | -74.6% | 53 |
The 6 top-ranked analysts at Guggenheim, the firm's full 3- and 5-year track record, and firm-vs-firm rankings across Wall Street. Everything below the top 6, plus 1- and 2-year history, stays free — Pro is what keeps this independent research running and the servers paid for.
Upgrade to ProDisclaimer: Firm-level performance is calculated independently by 13Foresight by pooling the historical calls of analysts associated with this firm, measured against market prices. It may be incomplete or delayed, is for research purposes only, and is not investment advice.